Format

Send to

Choose Destination
J Clin Invest. 2019 Mar 1;129(3):1387-1401. doi: 10.1172/JCI125456. Epub 2019 Feb 18.

CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen.

Author information

1
Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California, USA.
2
Rutgers Institute for Translational Medicine and Science, Rutgers University, New Brunswick, New Hampshire, USA.

Abstract

Allergen immunotherapy for patients with allergies begins with weekly escalating doses of allergen under medical supervision to monitor and treat IgE mast cell-mediated anaphylaxis. There is currently no treatment to safely desensitize mast cells to enable robust allergen immunotherapy with therapeutic levels of allergen. Here, we demonstrated that liposomal nanoparticles bearing an allergen and a high-affinity glycan ligand of the inhibitory receptor CD33 profoundly suppressed IgE-mediated activation of mast cells, prevented anaphylaxis in Tg mice with mast cells expressing human CD33, and desensitized mice to subsequent allergen challenge for several days. We showed that high levels of CD33 were consistently expressed on human skin mast cells and that the antigenic liposomes with CD33 ligand prevented IgE-mediated bronchoconstriction in slices of human lung. The results demonstrated the potential of exploiting CD33 to desensitize mast cells to provide a therapeutic window for administering allergen immunotherapy without triggering anaphylaxis.

KEYWORDS:

Glycobiology; Immunology; Mast cells; Nanotechnology; Therapeutics

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center